A call for using natural compounds in the development of new antimalarial treatments-an introduction

被引:103
|
作者
Ginsburg, Hagai [1 ]
Deharo, Eric [2 ,3 ]
机构
[1] Hebrew Univ Jerusalem, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel
[2] Univ Toulouse, UPS, Lab Pharmacochim Subst Nat & Pharmacophores Redox, UMR 152, F-31062 Toulouse 9, France
[3] Inst Rech Dev, UMR 152, Lima, Peru
关键词
PLASMODIUM-FALCIPARUM; PLANTS; PRODUCTS; MEDICINES; SYNERGY; AGENTS; ETHNOPHARMACOLOGY; ARTEMISININ; COMBINATION; FLAVONOIDS;
D O I
10.1186/1475-2875-10-S1-S1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Natural compounds, mostly from plants, have been the mainstay of traditional medicine for thousands of years. They have also been the source of lead compounds for modern medicine, but the extent of mining of natural compounds for such leads decreased during the second half of the 20(th) century. The advantage of natural compounds for the development of drugs derives from their innate affinity for biological receptors. Natural compounds have provided the best anti-malarials known to date. Recent surveys have identified many extracts of various organisms (mostly plants) as having antiplasmodial activity. Huge libraries of fractionated natural compounds have been screened with impressive hit rates. Importantly, many cases are known where the crude biological extract is more efficient pharmacologically than the most active purified compound from this extract. This could be due to synergism with other compounds present in the extract, that as such have no pharmacological activity. Indeed, such compounds are best screened by cell-based assay where all potential targets in the cell are probed and possible synergies identified. Traditional medicine uses crude extracts. These have often been shown to provide many concoctions that deal better with the overall disease condition than with the causative agent itself. Traditional medicines are used by similar to 80 % of Africans as a first response to ailment. Many of the traditional medicines have demonstrable anti-plasmodial activities. It is suggested that rigorous evaluation of traditional medicines involving controlled clinical trials in parallel with agronomical development for more reproducible levels of active compounds could improve the availability of drugs at an acceptable cost and a source of income in malaria endemic countries.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Call to Action: How Can We Promote the Development of New Pharmacologic Treatments in Chronic Obstructive Pulmonary Disease?
    Belz, Daniel C.
    Putcha, Nirupama
    Alupo, Patricia
    Siddharthan, Trishul
    Baugh, Aaron
    Hopkinson, Nick
    Castaldi, Peter
    Papi, Alberto
    Mannino, David
    Miravitlles, Marc
    Han, Meilan
    Fabbri, Leonardo M.
    de Oca, Maria Montes
    Krishnan, Jerry A.
    Singh, Dave
    Martinez, Fernando J.
    Hansel, Nadia N.
    Calverley, Peter
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 210 (11) : 1300 - 1307
  • [22] An Overview of New Possible Treatments of Alzheimer's Disease, Based on Natural Products and Semi-Synthetic Compounds
    Zanforlin, Enrico
    Zagotto, Giuseppe
    Ribaudo, Giovanni
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (34) : 3749 - 3773
  • [23] Development of new synthetic reactions using samarium compounds as catalysts
    Nishiyama, Y
    Sakaguchi, S
    Ishii, Y
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2000, 58 (02) : 129 - 137
  • [24] Development of new reactions of fluorine compounds using a rhodium catalyst
    Sato, Kazuyuki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2006, 126 (08): : 597 - 605
  • [25] Development of new synthetic reactions using samarium compounds as catalysts
    Ishii, Y
    Nishiyama, Y
    Kawasaki, Y
    Tashiro, D
    Shiraishi, H
    Sakaguchi, S
    REVIEWS ON HETEROATOM CHEMISTRY, 1997, 17 : 109 - 132
  • [26] Using genetic findings in autism for the development of new pharmaceutical compounds
    Vorstman, Jacob A. S.
    Spooren, Will
    Persico, Antonio M.
    Collier, David A.
    Aigner, Stefan
    Jagasia, Ravi
    Glennon, Jeffrey C.
    Buitelaar, Jan K.
    PSYCHOPHARMACOLOGY, 2014, 231 (06) : 1063 - 1078
  • [27] Using genetic findings in autism for the development of new pharmaceutical compounds
    Jacob A. S. Vorstman
    Will Spooren
    Antonio M. Persico
    David A. Collier
    Stefan Aigner
    Ravi Jagasia
    Jeffrey C. Glennon
    Jan K. Buitelaar
    Psychopharmacology, 2014, 231 : 1063 - 1078
  • [28] A search for natural bioactive compounds in Bolivia through a multidisciplinary approach Part IV.: Is a new haem polymerisation inhibition test pertinent for the detection of antimalarial natural products?
    Baelmans, R
    Deharo, E
    Bourdy, G
    Muñoz, V
    Quenevo, C
    Sauvain, M
    Ginsburg, H
    JOURNAL OF ETHNOPHARMACOLOGY, 2000, 73 (1-2) : 271 - 275
  • [29] A Brief Overview of Potential Treatments for Viral Diseases Using Natural Plant Compounds: The Case of SARS-Cov
    Abiri, Rambod
    Abdul-Hamid, Hazandy
    Sytar, Oksana
    Abiri, Ramin
    Bezerra de Almeida, Eduardo, Jr.
    Sharma, Surender K.
    Bulgakov, Victor P.
    Arroo, Randolph R. J.
    Malik, Sonia
    MOLECULES, 2021, 26 (13):
  • [30] Structure-based virtual screening approach reveals natural multi-target compounds for the development of antimalarial drugs to combat drug resistance
    Naik, Biswajit
    Gupta, Nidhi
    Godara, Priya
    Srivastava, Varshita
    Kumar, Prateek
    Giri, Rajanish
    Prajapati, Vijay Kumar
    Pandey, Kailash C.
    Prusty, Dhaneswar
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024, 42 (14): : 7384 - 7408